Duke logo

NRG-LU002 (Non-Small Cell Lung Cancer) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to compare using the usual drug therapy plus radiation to treat the lung cancer and areas where the cancer has spread compared with the usual drug therapy alone.

What is the Condition Being Studied?

Non-small cell lung cancer

Who Can Participate in the Study?

Adults 18 years of age or older with non-small cell lung cancer who:
- Are not pregnant or nursing
- have measurable disease
- have one site where cancer has spread

Age Group
Adults

What is Involved?

If you agree to be in the study you will:
- Be randomized (put into one of two groups by chance like a flip of a coin) and receive either:
Group 1 - the usual drug regimen alone
Group 2 - radiation to the lung tumor and other areas in the body where the cancer has spread, and possibly undergo surgery, followed by the usual drug regimen.

For both groups, after you stop the usual regimen your doctor will continue to watch you for side effects and follow your condition every 3 months for the first 2 years, every 6 months for the next 3 years, and then yearly afterwards.

Study Details

Full Title
NRG-LU002: Maintenance Systemic Therapy versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLS): A Randomized Phase II/III Trial
Principal Investigator
Medical Oncologist
Protocol Number
IRB:PRO00084715
NCT:NCT03137771
Phase
Phase II/III
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698